Activation of autophagy by erlotinib protects NSCLC cells with wild-type EGFR from erlotinib cytotoxicity

被引：1
|
作者：
Schwartz, Edward L. [1 ]
Ling, Yi-He [1 ]
Zou, Yiyu [1 ]
Piperdi, Bilal [1 ]
Perez-Soler, Roman [1 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-850
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
850
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
    Li, Yang-Ling
    Hu, Xiu
    Li, Qing-Yu
    Wang, Fei
    Zhang, Bo
    Ding, Ke
    Tan, Bi-Qin
    Lin, Neng-Ming
    Zhang, Chong
    MOLECULAR MEDICINE REPORTS, 2018, 18 (04) : 3882 - 3890
  • [2] RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR
    Nakahara, Yoshiro
    Hosomi, Yukio
    Yomota, Makiko
    Okuma, Yusuke
    Takagi, Yusuke
    Iguchi, Mari
    Okamura, Tatsuru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S490
  • [3] Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis
    Inno, Alessandro
    Di Noia, Vincenzo
    Martini, Maurizio
    D'Argento, Ettore
    Di Salvatore, Mariantonietta
    Arena, Vincenzo
    Schinzari, Giovanni
    Orlandi, Armando
    Larocca, Luigi Maria
    Cassano, Alessandra
    Barone, Carlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 513 - 520
  • [4] Predicting erlotinib resistance in EGFR wild type NSCLC patients.
    Jensen, Peter Buhl
    Knudsen, Steen
    Hansen, Anker
    Jensen, Thomas
    Askaa, Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Mechanism of epithelial-mesenchymal transition in erlotinib resistance in NSCLC cells containing both wild-type and mutant EGFR
    Singh, Sanjana
    Iderzorig, Tsatsral
    Kumar, Pragya
    Puri, Neelu
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors
    Toffalorio, Francesca
    de Marinis, Filippo
    Conforti, Fabio
    Spitaleri, Gianluca
    Catania, Chiara
    Noberasco, Cristina
    Lazzari, Chiara
    Vecchio, Fabio
    Stufano, Viviana
    Barberis, Massimo
    De Pas, Tommaso
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 392 - 396
  • [7] Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
    Winther-Larsen, Anne
    Fledelius, Joan
    Sorensen, Boe Sandahl
    Meldgaard, Peter
    LUNG CANCER, 2016, 94 : 81 - 87
  • [8] Erlotinib in EGFR wild type platinum resistant NSCLC: now a predictor factor
    Orlandi, A.
    Di Salvatore, M.
    Mannavola, F.
    Calegari, M. A.
    Inno, A.
    Bagala, C.
    Cassano, A.
    Astone, A.
    Barone, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S155 - S155
  • [9] Activity of gefitinib and erlotinib in pretreated EGFR wild-type NSCLC patients: A pooled analysis of 11 randomised trials
    Barni, S.
    Gregorc, V.
    Cabiddu, M.
    Ghilardi, M.
    Borgonovo, K.
    Coinu, A.
    Cremonesi, M.
    Vigano, M. G.
    Petrelli, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S824 - S825
  • [10] PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
    Zhou, Xin
    Wang, Xiaowen
    Zhu, Hongge
    Gu, Guomin
    Zhan, Yiyi
    Liu, Chunling
    Sun, Gang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
12345